The 4-year durability and safety data de-risk the BIM-IOL System's Phase 3 program and support a clear regulatory path. Watch for Phase 3 enrollment completion and FDA meeting outcomes as the next catalysts toward NDA submission.
Price Chart
Executive Summary
SpyGlass Pharma announced positive 4-year first-in-human trial results for its Bimatoprost Drug Pad-IOL System, showing a 37% mean IOP reduction and 86% of patients off topical drops with no product-related adverse events. The data supports the company's ongoing Phase 3 program and plans for a 505(b)(2) NDA submission, representing a significant clinical milestone for a late-stage biotech with a novel sustained-delivery platform.
Key Facts
- 37% reduction in mean IOP across all dose groups at 4 years (from 25.1 mmHg baseline to 15.9 mmHg)
- 86% (18/21) of evaluable patients remained off all topical IOP-lowering drops at 4 years
- 90% of patients maintained ≥20/25 BCDVA
- No product-related adverse events reported
- Phase 3 trials ongoing; company plans 505(b)(2) NDA submission with FDA
- Approximately 1 million cataract procedures annually in the US in patients with glaucoma
Financial Impact
Not stated — no revenue, market size, or financial projections provided
Risk Factors
- Phase 3 trials are ongoing and may not replicate FIH safety/efficacy results
- Regulatory approval is not guaranteed; FDA may require additional data
- Commercial adoption depends on surgeon workflow integration and reimbursement
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383361 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 8-K | $26.16 $27.71 | ▲ +5.93% | ▲ +5.40% | $29.47 (+12.65%) |
Oct 19, 2026 7d ago | Press Release | $24.60 $26.16 | ▲ +6.34% | ▲ +6.01% | $29.47 (+19.80%) |
Oct 1, 2026 25d ago | 8-K | $26.50 $24.92 | ▼ −5.96% | ▼ −6.70% | $29.47 (+11.21%) |
Oct 1, 2026 25d ago | Press Release | $26.50 $24.92 | ▼ −5.96% | ▼ −6.70% | $29.47 (+11.21%) |
May 14, 2026 23w ago | 8-K | $23.21 $22.24 | ▼ −4.18% | ▼ −4.12% | $29.47 (+26.97%) |
Mar 26, 2026 30w ago | Press Release | $22.61 $23.37 | ▲ +3.36% | ▲ +3.72% | $29.47 (+30.34%) |
Mar 9, 2026 33w ago | Press Release | $27.12 $26.82 | ▼ −1.11% | ▼ −0.92% | $29.47 (+8.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers